1月8日，盈康生命通过投资者互动平台表示，公司已建立覆盖术前筛查、术中实施到术后监控、康复的 脑机接口治疗帕金森全流程管理方案，旗下运城医院完成20余例脑起搏器植入术（DBS），为帕金森患 者提供创新治疗方案。 ...

格隆汇1月8日丨盈康生命(300143.SZ)在投资者互动平台表示，公司已建立起覆盖术前筛查、术中实施 到术后监控、康复的脑机接口治疗帕金森全流程管理方案，旗下运城医院完成20余例脑起搏器植入术 （DBS），为帕金森患者提供创新治疗方案。公司始终密切关注包括脑机接口在内的前沿技术在医疗健 康领域的应用与发展，持续深化技术优势，优化诊疗方案，不断增强公司在医疗服务领域的竞争力。 ...

（六）培训对象：公司董事、高级管理人员、中层以上管理人员及其他相关 人员，公司控股股东、实际控制人的相关人员 国泰海通证券股份有限公司 关于盈康生命科技股份有限公司 2025 年度持续督导培训情况报告 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为盈 康生命科技股份有限公司（以下简称"盈康生命"或"公司"）2020年非公开发 行股票、2022年向特定对象发行股票的持续督导机构，根据《证券发行上市保荐 业务管理办法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公 司规范运作》《深圳证券交易所上市公司自律监管指引第13号——保荐业务》等 相关法律、法规和规范性文件的要求，对盈康生命进行了2025年度持续督导培训， 现将本次培训的具体情况报告如下： 一、本次培训的基本情况 （一）保荐人：国泰海通证券股份有限公司 三、上市公司的配合情况 本次培训期间，公司及培训对象积极配合保荐人的培训工作，保证了培训工 作的有序进行，达到了良好效果。 四、本次培训的结论 本次培训加强了公司相关人员对上市公司规范运作和信息披露相关法律法 规的理解与认识，有助于公司进一步提高规范运作和信息披露水平。本次培训 ...

（文章来源：证券日报） 证券日报网讯 1月5日，盈康生命在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东 总数为20327户。 ...

Core Viewpoint - The high-pressure oxygen chamber concept has seen a significant increase of 7.01%, ranking second among concept sectors, with notable stocks experiencing substantial gains, including a 30% surge for Beiyikang and limit-up performances for International Medicine and Innovative Medical [1][2]. Group 1: Market Performance - The high-pressure oxygen chamber sector had 10 stocks rising, with Beiyikang leading at a 30% increase, followed by International Medicine at 15.18% and Innovative Medical at 5.25% [1]. - The sector attracted a net inflow of 389 million yuan from main funds, with Innovative Medical receiving the highest net inflow of 256 million yuan [2][3]. Group 2: Fund Flow Analysis - The top three stocks in terms of net inflow ratio were Innovative Medical at 74.84%, International Medicine at 41.60%, and Yingkang Life at 8.97% [3]. - The trading performance of key stocks included Innovative Medical with a 10% increase and a turnover rate of 3.48%, while International Medicine rose by 10.02% with a turnover rate of 2.62% [3].

Group 1 - The high-pressure oxygen chamber concept has seen a significant increase of 7.01%, ranking second among concept sectors, with 10 stocks rising, including BeiYikang which hit a 30% limit up, and others like International Medicine and Innovation Medical also reaching their limit up [1] - The main inflow of funds into the high-pressure oxygen chamber concept amounted to 389 million yuan, with Innovation Medical receiving the highest net inflow of 256 million yuan, followed by International Medicine and Yingkang Life [2][3] - The net inflow ratios for major stocks in the high-pressure oxygen chamber concept are led by Innovation Medical at 74.84%, International Medicine at 41.60%, and Yingkang Life at 8.97% [3] Group 2 - The top-performing concept sectors today include Brain-Computer Interface with a rise of 13.70%, while the Free Trade Zone saw a decline of 2.93% [2] - Other notable sectors include Blood Oxygen Meters up 5.65% and 2025 Annual Report Pre-Increase up 5.16% [2] - The trading volume and turnover rates for stocks in the high-pressure oxygen chamber concept indicate active trading, with Innovation Medical showing a turnover rate of 3.48% [3]

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

Group 1 - The core business of Yingkang Life includes medical devices and medical services, with medical services accounting for 77.47% of revenue and medical devices 22.53% [2] - As of December 19, the number of shareholders of Yingkang Life is 20,100, a decrease of 0.14% from the previous period, with an average of 31,929 circulating shares per person, an increase of 0.14% [2] - For the period from January to September 2025, Yingkang Life achieved operating revenue of 1.358 billion yuan, a year-on-year increase of 10.59%, and a net profit attributable to shareholders of 86.839 million yuan, a year-on-year increase of 5.20% [2] Group 2 - On December 29, Yingkang Life's stock price fell by 1.39%, with a trading volume of 54.3424 million yuan [1] - The financing buy-in amount on December 29 was 8.3047 million yuan, while the financing repayment was 9.973 million yuan, resulting in a net financing buy-in of -1.6683 million yuan [1] - The total balance of margin trading for Yingkang Life as of December 29 is 234 million yuan, with the financing balance accounting for 3.66% of the circulating market value, indicating a high level compared to the past year [1]

场的良性互动机制。 盈康生命此次获奖，是对其IR团队专业能力与系统化投资者关系管理体系的权威肯定。作为聚焦医疗健康领域的上市企业，盈康生命始终将投资者关系管理 视为连接企业与资本市场的重要桥梁，依托专业IR团队构建了全方位、多层次的投资者沟通体系。在信息披露方面，公司严格遵循监管要求，确保信息披露 的真实、准确、完整、及时与公平，为投资者全面了解公司经营状况与发展战略提供清晰指引，有效稳定了市场预期。 12月26日，以"新开局、新动能、新征程"为主题的"启航·2025金融峰会"在北京圆满举办，大会由金融界主办，汇聚监管部门、行业协会、金融机构、上市 公司、媒体等数百位相关领导和重磅嘉宾。会上，第十四届金融界"金智奖"年度评选结果重磅揭晓，盈康生命荣获"杰出投资者关系（IR）团队奖"。 "金智奖"旨在树立高质量发展标杆，引导上市公司聚焦主业、持续创新、践行社会责任，推动资本向优质企业集聚。本届评选中，金融界上市公司研究院紧 密契合"十五五"规划建议中"提升上市公司质量"的要求，将高质量发展内核分解为社会责任、实业贡献、投资回报、成长前景、创新效率、杰出品牌六大维 度，以企业财务数据和公开信息为基础建立量化分析模 ...

Group 1 - The high-pressure oxygen chamber concept declined by 0.92%, ranking among the top declines in the concept sector, with companies like Innovation Medical, Aoyang Health, and Yinkang Life experiencing significant drops [1] - Among the concept stocks, Jinling Pharmaceutical, Tiedao Heavy Industry, and Hangyang Co. saw increases of 2.93%, 0.77%, and 0.26% respectively [1] - The top-performing concept sectors today included Hainan Free Trade Zone with a rise of 4.32%, and various metal sectors such as zinc and lead, which increased by 3.61% and 3.30% respectively [1] Group 2 - The high-pressure oxygen chamber concept experienced a net outflow of 199 million yuan, with six stocks seeing significant outflows, led by Innovation Medical with a net outflow of 132 million yuan [1] - Other companies with notable net outflows included Hangyang Co. and Yinkang Life, with outflows of 39.31 million yuan and 12.35 million yuan respectively [1] - Conversely, Aoyang Health, Jinling Pharmaceutical, and Dahu Co. were among the stocks with net inflows, receiving 2.49 million yuan, 2.04 million yuan, and 0.47 million yuan respectively [1]